Molecular Partners AG Sponsored ADR (MOLN)
(Delayed Data from NSDQ)
$3.70 USD
-0.18 (-4.64%)
Updated Apr 29, 2024 03:56 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
MOLN 3.70 -0.18(-4.64%)
Will MOLN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MOLN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MOLN
Biotech Stock Roundup: BIIB's AD Drug Update, AMGN's Drug Approval & Other Updates
MOLN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MOLN
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
Life Science Cares Launches in Switzerland
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
Molecular Partners Publishes Invitation to Annual General Meeting 2024
Molecular Partners Sets Date for 2024 AGM